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Mutations in LRRK2 are a common cause of familial and idiopathic Parkinson’s disease
(PD). Recently, the LRRK2 GTPase domain R1398H variant was suggested in genetic
studies to confer protection against PD but mechanistic data supporting this is lacking.
Here, we present evidence that R1398H affects GTPase function, axon outgrowth,
and Wnt signaling in a manner opposite to pathogenic LRRK2 mutations. LRRK2
R1398H GTPase domain dimerization and GTP hydrolysis were increased whereas
GTP binding was reduced, leading to a decrease in active GTP-bound LRRK2.
This protective variant also increased axon length of primary cortical neurones in
comparison to wild-type LRRK2, whereas the R1441G LRRK2 pathogenic mutant
decreased axon outgrowth. Importantly, R1398H enhanced the stimulatory effect of
LRRK2 on canonical Wnt signaling whereas the G2385R risk variant, in accordance
with all previously tested pathogenic LRRK2 mutants, had the opposite effect. Molecular
modeling placed R1398H in close proximity to PD-causing mutations suggesting that
this protective LRRK2 variant, like familial mutations, affects intramolecular RocCOR
domain interactions. Thus, our data suggest that R1398H LRRK2 is a bona fide
protective variant. The opposite effects of protective versus PD associated LRRK2
variants on GTPase function and canonical Wnt signaling activity also suggests that
regulation of these two basic signaling mechanisms is important for neuronal function.
We conclude that LRRK2 mediated Wnt signaling and GTPase function are fundamental
in conferring disease susceptibility and have clear implications for therapeutic target
identification.
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INTRODUCTION
Autosomal-dominant mutations in LRRK2, encoding leucine-rich repeat kinase 2 (LRRK2), are
the most common known cause of inherited Parkinson’s disease (PD; Paisán-Ruíz et al., 2004;
Zimprich et al., 2004). Patients with LRRK2 mutations display symptoms and brain pathologies that
are largely indistinguishable from those of individuals with idiopathic PD (Paisán-Ruíz et al., 2004;
Zimprich et al., 2004; Ross et al., 2006; Kumari and Tan, 2009). Thus, determining the biological
role of LRRK2 is of paramount importance to understanding the etiology of PD, and likely to help
uncover new therapeutic strategies.
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LRRK2 is a multifunctional protein containing both kinase
and GTPase activities and a number of protein–protein
interaction domains (Figure 1). The ‘catalytic core’ is contained
within the Roc (Ras of complex proteins), COR (C-terminal
of Roc) and kinase domains (Figure 1) and appears essential
for LRRK2 function (Berwick and Harvey, 2011). As the only
hereditary mutations that are proven to cause PD fall within
exons coding for the Roc, COR and kinase domains, the effects
of pathogenic mutations on LRRK2 enzymatic activities require
further investigation.
The precise extent of the LRRK2 GTPase domain remains
controversial. Restricting the LRRK2 GTPase domain to the Roc
domain can be justified by the similarity to Ras family small
GTPases. Arguing against this are, the observations that isolated
Roc protein appears to hydrolyse GTP at a greatly reduced rate
compared to full-length LRRK2 (Gilsbach and Kortholt, 2014)
and that throughout evolution, Roc and COR domains never
occur without each other (Bosgraaf and van Haastert, 2003). This
supports the definition of a LRRK2 GTPase “RocCOR tandem”
domain.
Based on homology to C. tepidum Roco protein, the
LRRK2 RocCOR tandem is predicted to fall into the GAD (G
proteins activated by nucleotide-dependent dimerization) class
of molecular switches (Gotthardt et al., 2008; Gasper et al.,
2009; Gilsbach and Kortholt, 2014). Under the GAD model, two
LRRK2 molecules are expected to dimerize via a constitutive
interaction between the COR domains holding the two Roc
domains in close proximity (Figures 1 and 3A,B). Binding
of GTP to the Roc domains results in protein dimerization
allowing binding of effector proteins. GTP hydrolysis disrupts
Roc dimerization, leading to the dissociation of effector proteins
(Gotthardt et al., 2008; Gasper et al., 2009; Gilsbach and Kortholt,
2014).
FIGURE 1 | LRRK2 domain structure and proposed function as a GAD
GTPase. (A) The domain structure of LRRK2 and location of key pathogenic
mutations and PD risk variants (∗) is depicted. Note the central catalytic core
consisting of the RocCOR tandem and kinase domains. (B) The assumed
behavior of the LRRK2 RocCOR tandem as a GAD protein is represented
graphically. In this model, COR domains are a constitutive dimerization device,
whilst Roc domains cycle between a GDP-bound and monomeric ‘off’ state,
and a GTP-bound and dimeric ‘on’ state.
All known PD-causing mutations located within the LRRK2
RocCOR domain have been reported to increase GTP-binding,
decrease GTPase activity, or both (Table 1) supporting the
idea that shifting LRRK2 to the GTP-bound ‘on’-state promotes
neurodegeneration.
A consensus on the cellular role of LRRK2 is still lacking,
with numerous competing – though not mutually exclusive –
functions reported. Nonetheless, a comprehensive literature
review identified cell biological processes involving LRRK2 that
appear to be reproducible (Berwick and Harvey, 2013) including
effects on membrane trafficking (Piccoli et al., 2011; Ramonet
et al., 2011; reviewed by Gómez-Suaga et al., 2014), cytoskeletal
function (Parisiadou et al., 2009; Law et al., 2014; reviewed by
Gómez-Suaga et al., 2014) and signal transduction pathways
including MAPK, Wnt, TLR, and NFAT pathways (Berwick and
Harvey, 2011; Boon et al., 2014; reviewed by Gómez-Suaga et al.,
2014).
A growing body of data supports the importance of
deregulated canonical Wnt signaling in neurodegenerative
disease pathogenesis, including PD (Berwick and Harvey,
2014; Inestrosa and Varela-Nallar, 2014). At least six proteins
implicated in PD have been described to modulate this pathway,
whilst development of the midbrain dopaminergic neurones that
are typically lost in PD is acutely dependent on canonical Wnt
signaling (Berwick and Harvey, 2014). Furthermore, decreased
Wnt signaling has been reported in PD patients (Cantuti-
Castelvetri et al., 2007), as well as in various animal models
of parkinsonism (L’Episcopo et al., 2011; Gollamudi et al.,
2012). Since Wnt ligands are well established as neuroprotective
(Berwick and Harvey, 2014; Inestrosa and Varela-Nallar, 2014),
the idea that decreased canonical Wnt signaling is involved
in PD pathogenesis is an attractive hypothesis. Importantly,
evidence for a crucial role of LRRK2 in canonical Wnt signaling
is accumulating. Protein–protein interactions between LRRK2
and a number of Wnt signaling components have been reported,
including interactions with disheveled (DVL) proteins, the
serine/threonine kinase GSK3β, and LRP6, a Wnt signaling
transmembrane receptor (Sancho et al., 2009; Lin et al., 2010;
Berwick and Harvey, 2012). Furthermore, over-expressed wild-
type LRRK2 enhances the signal strength of activated canonical
Wnt signaling (Berwick and Harvey, 2012). Intriguingly, this
effect of LRRK2 is weakened by PD-causing mutations in three
distinct catalytic domains of LRRK2 – R1441C in the Roc
domain, Y1699C in the COR domain, and G2019S in the kinase
domain (Berwick and Harvey, 2012) – suggesting that impaired
Wnt signaling is a common pathogenic mechanism of familial
LRRK2 mutations.
Recently, a number of genetic screens have reported an
inherited R1398H LRRK2 variant in the Roc domain (Chen
et al., 2010; Tan et al., 2010; Ross et al., 2011; Heckman et al.,
2013, 2014) that appears to confer decreased risk of PD. This
could prove extremely informative, since a protective variant
can be expected to display the opposite behavior to pathogenic
variants in disease-relevant assays. In a single study, R1398H was
reported to display decreased kinase activity compared to wild-
type LRRK2 (Tan et al., 2010). However, this observation should
be treated with caution, as this study also found the G2385R
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TABLE 1 | The effect of PD-causing mutations in the LRRK2 RocCOR tandem domain on GTP-binding and GTPase activity.
Mutation LRRK2 construct GTP binding GTP hydrolysis Prediction Reference
N1437H Full length ↑ ns ↑ GTP-bound Aasly et al., 2010
R1441C Full length ↑ ns ↑ GTP-bound West et al., 2007
R1441C Full length — ↓ ↑ GTP-bound Li et al., 2007
R1441C Full length — ↓ ↑ GTP-bound Lewis et al., 2007
R1441C Roc ns ↓ ↑ GTP-bound Deng et al., 2008
R1441C Full length ns ↓ ↑ GTP-bound Xiong et al., 2010
R1441C Roc, COR, kinase — — No change Xiong et al., 2010
R1441C 970-2527 ns ↓ ↑ GTP-bound Pungaliya et al., 2010
R1441C Full length ↑ ns ↑ GTP-bound Stafa et al., 2012
R1441G Full length ↑ ns ↑ GTP-bound West et al., 2007
R1441G Full length — ↓ ↑ GTP-bound Li et al., 2007
R1441G Full length ns ↓ ↑ GTP-bound Xiong et al., 2010
R1441H Roc ↑ ↓ ↑ GTP-bound Liao et al., 2014
“R1441”A C. tepidum RocCOR — ↓ ↑ GTP-bound Gotthardt et al., 2008
Y1699C Full length ↑ ns ↑ GTP-bound West et al., 2007
Y1699C Full length ns ↓ ↑ GTP-bound Xiong et al., 2010
Y1699C Full length — ↓ ↑ GTP-bound Daniëls et al., 2011
Y1699C Full length ↑ ns ↑ GTP-bound Stafa et al., 2012
“Y1699”C C. tepidum RocCOR — ↓ ↑ GTP-bound Gotthardt et al., 2008
Based on published data, the pathogenic N1437H, R1441C, R1441G, R1441H, and Y1699C mutations all elicit an increase in the fraction of GTP-bound LRRK2. Only
one construct, an R1441C RocCOR-kinase, displayed no changes in GTP-binding or GTP hydrolysis; however, this mutation decreased GTPase activity in full length
LRRK2 in the same publication. Note that mutations at residues equivalent to R1441 and Y1699 in C. tepidum Roco protein produce consistent results. Key: up and
down arrows represent increases and decreases, respectively; dashes represent no change; ‘ns’ indicates ‘not studied.’
risk variant to have increased kinase activity, in contrast to other
reports (Jaleel et al., 2007; West et al., 2007; Nichols et al., 2010;
Rudenko et al., 2012). In any case, the need to elucidate the
functional relevance of the R1398H experimentally is clear.
Here, we report the behavior of the LRRK2 R1398H variant in
five assays for which the effect of a bona fide protective mutation
in the LRRK2 Roc domain can be predicted: LRRK2 RocCOR
tandem domain dimerization, LRRK2 GTP-binding, LRRK2
GTPase assays, axon outgrowth, and canonical Wnt signaling
assays. Remarkably, R1398H displays the opposite behavior to
pathogenic mutants in all experiments. Furthermore, molecular
modeling studies suggest that this amino acid substitution is
likely to affect intramolecular RocCOR interactions, consistent
with the predicted mode of action for PD-causing mutations
in the RocCOR tandem. Thus our data (1) provide strong
experimental support for the status of LRRK2 R1398H as a
genuine protective variant; (2) increase the weight of evidence
that GTP-bound LRRK2 is pathogenic; and (3) provide further
data indicating that decreased canonical Wnt signaling is a key
pathomechanism underlying PD.
MATERIALS AND METHODS
Molecular Cloning
pDS-BAIT (pDS; Dualsystems Biotech) plasmids containing
the LRRK2 Roc and RocCOR domains (encoding amino acids
1330–1515 and 1335–1845, respectively), pACT2 (Clontech)
containing the LRRK2 RocCOR domain and pYTH16 containing
the intracellular domain of LRP6 (amino acids 1416–1613)
have been described previously (Daniëls et al., 2011; Berwick
and Harvey, 2012). pCHMWS vectors expressing 3× FLAG-
tagged wild-type LRRK2 and LRRK2-T1348N were a generous
gift from Dr. Jean-Marc Taymans (Daniëls et al., 2011). pRK5
myc-LRRK2 has also been described previously (Sancho et al.,
2009). R1398H, R1398H/R1441G and G2385R mutations were
introduced using the QuikChange Lightening site-directed
mutagenesis kit (Agilent) according to the manufacturer’s
instructions. All constructs were verified by DNA sequencing.
Culture of Immortalized Cell Lines
HEK293 cells and SH-SY5Y cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
(v/v) fetal bovine serum, 100 U/ml penicillin G and 100 µg/ml
streptomycin at 37◦C and 5% CO2. Transient transfection
was performed using FuGENE HD (Roche) according to the
manufacturer’s instructions, using a 2.5 µL transfection reagent
to 1 µg DNA ratio. In all cases, cells were harvested 24 h after
transfection.
Quantitative Yeast-Two Hybrid
The L40 yeast strain (Invitrogen) was co-transformed with pDS
Roc or RocCOR bait and pACT2 wild-type or mutant RocCOR
prey constructs, and the Y190 yeast strain (Clontech) was co-
transformed with the pYTH16 LRP6 intracellular domain bait
and pACT2 wild-type or mutant RocCOR prey constructs.
Transformations were spread on selective dropout media
(Clontech) lacking leucine and tryptophan for transformation
controls, or leucine, tryptophan and histidine, supplemented with
0.5 mM 3-aminotriazole (L40 strain) or 10 mM 3-aminotriazole
(Y190 strain; for suppression of ‘leaky’ histidine expression;
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Sigma-Aldrich) for nutritional selection. After incubation at
30◦C for 3 days, prototrophic colonies were picked and used
to inoculate minimal SD (Clontech) media lacking leucine and
tryptophan. Samples were subsequently incubated shaking at
30◦C overnight. Cell pellets were then resuspended in Z-buffer
(60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM
MgSO4.7H2O) containing 40 mM β-mercaptoethanol, followed
by lysis in 0.1% (w/v) SDS (Sigma-Aldrich) and 0.1% (v/v)
chloroform (Sigma-Aldrich). After the addition of chloropheno-
red-β-D-galactopyranoside (Sigma-Aldrich), the color change
was recorded at 540 nm and readings adjusted for turbidity of
the yeast suspension at 620 nm. The background signal (bait
plus empty pACT2 vector) was subtracted from each reading
and values were normalized to the wild-type RocCOR response,
which was set at 100%. All protein interactions were assayed in
three to five independent experiments in triplicate.
Molecular Modeling
Molecular modeling was performed on the C. tepidum Roco
structure (PDB: 3DPU; Gotthardt et al., 2008) using Chimera
(Pettersen et al., 2004). Amino acid substitutions were performed
with the swapaa command using the Dunbrack backbone-
dependent rotamer library (Dunbrack, 2002).
GTP-Binding Assay
HEK293 cells were transfected with 3× FLAG-tagged T1348N,
R1398H or wild-type LRRK2. The GTP binding assay was
performed similarly as described by others (Korr et al., 2006).
Briefly, cells were lysed for 10 min on ice in lysis buffer G
(100 mM Tris/HCl pH 7.5, 50 mM KCl, 1 mM EDTA, 0.1 mM
DTT, 5 mM MgCl2, 1% Triton X-100, protease inhibitor cocktail,
Roche), and lysates were centrifuged for 10 min at 20,000 g and
4◦C. Supernatants containing 100 µg protein each, as assessed by
QuickStart Bradford assay (Bio-Rad), were incubated for 80 min
at 4◦C with 30 µl of GTP-Sepharose bead suspension (Sigma)
that was pre-treated with 100 µg/ml BSA (Pierce) at 4◦C for
1 h. Samples were washed three times with 500 µl lysis buffer
G, before bound protein was eluted using 100 µM GTP in
lysis buffer G. The resulting eluate was added to 1× NuPAGE
sample buffer (Invitrogen) and heated for 6 min at 96◦C.
The eluates were analyzed by SDS-PAGE and immunoblotting.
Initially, protein was loaded into 4–12% (w/v) BisTris pre-cast
gels (Invitrogen), prior to transfer to polyvinylidine fluoride
membranes (Millipore). Non-specific bands were blocked for 1 h
at 37◦C with 5% (w/v) skimmed milk in PBS plus 0.1% (v/v)
Tween 20. Anti-Calnexin antibody (Abcam) was used at 1:4000,
and anti-FLAG antibody (Sigma-Aldrich) was used at 1:3000
at 4◦C overnight. For detection, an HRP-conjugated anti-rabbit
secondary antibody (Santa Cruz Biotechnology) was used at a
final dilution of 1:2000, together with the SuperSignal West Pico
Chemiluminescent Substrate (Pierce).
GTPase Assay
GTPase assays were carried out according to Daniëls et al.
(2011). Initially, HEK293 cells were transfected with 3× FLAG-
tagged T1348N, R1398H or wild-type LRRK2 and lysed after
24 h in GTPase lysis buffer [20 mM Tris/HCl pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 10% Glycerol, protease
inhibitor cocktail (Roche), phosphatase inhibitor cocktail 2
(Sigma-Aldrich)]. Cell lysates were clarified as above, added
to 40 µl of anti-FLAG M2 affinity gel (Sigma-Aldrich) and
incubated overnight at 4◦C on a turning disk in order to purify
the FLAG-tagged proteins. The affinity gel was subjected to
centrifugation (4◦C, 100 g, 3 min), followed by two washes in
GTPase lysis buffer and a brief rinse in GTPase buffer (20 mM
Tris/HCl pH 7.5, 150 mM NaCl, 10 mM MgCl2, 0.02% Triton
X-100). Proteins were eluted from beads with 3× FLAG peptide
(Sigma-Aldrich) in GTPase buffer according to manufacturer’s
instructions. The protein concentration of eluates were calculated
from a serial BSA dilution curve, with purity assessed by running
a small volume of each sample on an SDS-PAGE gel and staining
with GelCode Blue Stain Reagent (Pierce). GTPase assays were
performed according to Margalit et al. (2004) using 80 nM
LRRK2 protein in GTPase buffer containing 20 U/ml pyruvate
kinase (EC 2.7.1.40)/lactate dehydrogenase (EC 1.1.1.27; Sigma-
Aldrich), 600 µM NADH (Sigma-Aldrich), 1 mM PEP (Sigma-
Aldrich) and 500 µM GTP (Sigma-Aldrich) in a final volume
of 200 µl. Reaction mixes were equilibrated to 30◦C for 10 min
before the reactions were initiated by the addition of GTP
and thorough mixing of the contents. Depletion of NADH was
measured by monitoring the decrease in absorbance at 340 nm
every 5 min across a 50 min period using a VersaMax microplate
reader (Molecular Devices).
Primary Cortical Neuronal Cultures
Primary cultures of rat cortical neurones were prepared from
E18 embryos obtained from timed-pregnant Sprague-Dawley rats
(Taconic Biosciences, Hudson, NY, USA) narcotized with CO2
(in cylinders) then decapitated using a guillotine. All animal
studies were approved by the National Institute of Neurological
Disorders and Stroke/National Institute on Deafness and Other
Communication Disorders Animal Care and Use Committee
(Protocol 1151-12). Neurones were transfected with wild-type
and mutant myc-tagged LRRK2 using the Amaxa Rat Neuron
Nucleofector Kit, program 0-03, according to the manufacturer’s
protocol (Lonza Group, Basel, Switzerland). Neurones were then
plated at a density of approximately 2.6 × 104/cm2 on cover
slips and maintained as described previously (Zhu et al., 2006).
At 7 days in vitro (DIV) neurones were fixed for 10 min
with 4% paraformaldehyde, and permeabilized for 15 min with
0.05% Triton-X (Sigma-Aldrich) prior to a 1 h block in 5%
NGS (GIBCO). Slides were then immunostained with primary
and Alexa Fluor secondary antibodies, mounted using ProLong
gold (Life Technologies), and imaged using a Zeiss LSM710
laser-scanning confocal microscope. Primary antibodies against
the following proteins were used: myc-epitope (Santa Cruz
Biotechnology), MAP2 (Abcam) and Tau-1 (Abcam). Alexa Fluor
488 (rabbit), 555 (mouse) and 633 (goat) secondary antibodies
(Thermo Scientific) were used against myc, tau and MAP-2
epitopes respectively.
Axon Length Measurements
Axon outgrowth properties of neurones were quantified
manually. Three to six coverslips from three independent
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FIGURE 2 | R1398H increases LRRK2 RocCOR dimerization. Quantitative YTH assays reveal that the presence of an R1398H variant in the RocCOR prey
constructs (A) increases the interaction strength with a RocCOR bait whereas the pathogenic R1441G mutant has the opposite effect (one-way ANOVA for effect of
genotype, F = 39.286, p < 0.001; n = 5). Values shown are the means of five independent experiments. (B) The R1398H variant also increases the interaction
strength with an isolated Roc domain bait whilst the pathogenic R1441G, R1441H, and Y1699C LRRK2 mutations weaken interaction strength (one-way ANOVA for
effect of genotype, F = 34.729, p < 0.001; n = 3–6). (C) All LRRK2 mutant constructs express at an equivalent level to wild-type LRRK2. Values shown are the
means of at least three independent experiments. p-values for post hoc Dunnett’s testing relative to wild-type LRRK2 are shown. Error bars represent the standard
error of the mean.
experiments for each genotype were analyzed. Axonal
outgrowth and branching of dissociated neurones were
quantified manually and verified using the NeuronJ plugin
for ImageJ. Transfected neurones were identified using the
myc-epitope antibody, whilst the length of the longest Tau-1
stained process from each neurone was measured. At least 40
neurones were quantified for each genotype, myc vector control,
myc-LRRK2 wild-type, myc-LRRK2 R1398H, myc-LRRK2
R1441G, and myc-LRRK2 R1398H/R1441G from at least three
coverslips.
Luciferase Assays
Canonical Wnt activity was measured using the TOPflash
reporter plasmid (Veeman et al., 2003) in human dopaminergic
SH-SY5Y cells as described previously (Berwick and Harvey,
2012). Cells were extracted 24 h post-transfection using
Passive Lysis Buffer (Promega) and assays performed using
a Dual Luciferase Reporter Assay kit (Promega) and Turner
Instruments 20/20 luminometer. Luciferase values were
normalized to co-transfected Renilla plasmid to adjust for
transfection efficiency, and then corrected to values from parallel
experiments performed using the FOPflash control plasmid
(Veeman et al., 2003).
Statistical Analysis
GTPase assays (Figure 4D) were tested by two-way ANOVA
with repeated measures, with the independent variables genotype,
time, and time × genotype, followed by post hoc analysis by
two-sided Dunnett’s testing. Axonal branching was assessed by
Kruskal–Wallis (Figure 6B) or Mann–Witney (Supplementary
Figure S2A) tests. Axon length was analyzed by one-way ANOVA
followed by Bonferroni post hoc analysis (Figure 6C) or Student’s
t-test (Supplementary Figure S2B). For axon length analysis,
outliers (values defined as differing from the mean by 2 or more
standard deviations) were first excluded. All other experiments
were analyzed by one-way ANOVA for the effect of genotype
followed by a two-sided Dunnett’s test with wild-type LRRK2
considered the control. Student’s t-test was performed using
Excel, all other statistics were performed with SPSS software. All
error bars represent the standard error of the mean.
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RESULTS
In Contrast to LRRK2 GTPase Mutants
Causing PD, R1398H Increases RocCOR
Dimerization
To investigate functional effects of R1398H, we studied this
variant in assays of LRRK2 RocCOR domain dimerization.
These sensitive quantitative yeast-two hybrid (Q-YTH) assays
have been used previously in our laboratory to show that
the PD-causing R1441C, R1441G, R1441H, and Y1699C
mutations significantly weaken RocCOR domain dimerization
(Daniëls et al., 2011). Intriguingly, R1398H elicited an effect
opposite to these pathogenic mutations, with increased RocCOR
dimerization observed (Figure 2A). The R1441G mutant was
studied as a pathogenic control showing as expected a significant
decrease in RocCOR dimerisation (Figure 2A). Consistently,
R1398H also strengthened interaction between the LRRK2
RocCOR tandem domain and an isolated wild-type LRRK2 Roc
domain, whilst the R1441G, R1441H, and Y1699C pathogenic
mutations weakened this interaction (Figure 2B). R1441C was
also studied in this experiment, displaying a non-significant trend
toward decreased interaction (Figure 2B). These effects were
not due to changes in protein expression (Figure 2C). Thus,
in contrast to proven PD-causing RocCOR mutations, R1398H
enhanced intermolecular dimerization within the LRRK2 GTPase
domain.
Molecular Modeling Suggests that
LRRK2 R1398H Affects Intramolecular
RocCOR Interaction
To examine the molecular mechanism underlying altered
RocCOR dimerization, the predicted location of R1398 was
examined by molecular modeling of the closest available protein
structure: the RocCOR tandem domain of C. tepidum Roco
protein (Gotthardt et al., 2008). Supporting the importance
of R1398 in RocCOR dimerization, the equivalent residue in
Roco (Q519) resides on the internal face of each Roc domain.
To examine the role of human R1398, this amino acid was
swapped to arginine in our model (Figure 3C). Using the
most probable rotamer conformation, the long basic side chain
of arginine projected toward the COR domain of the same
molecule. Indeed, R1398 was predicted to bond with the hydroxyl
FIGURE 3 | R1398H is predicted to affect intramolecular RocCOR interactions. (A) The topology of the dimeric RocCOR tandem domain from C. tepidum
Roco protein is shown as a space-filled structure, viewed from two orientations. Roc and COR domains are labeled. For clarity, the Roc and COR domains of one
molecule are depicted in shades of blue, the domains of the second molecule are yellow. (B) A magnified top view of the Roco dimer as a ribbon model. The internal
location on both Roco molecules of the equivalent residue to human R1398 is colored red, and labeled. Arginine side chains are shown. (C) A magnified image of
the modeled R1398, showing the arginine side chain projecting toward the equivalent residue S1671 in human LRRK2. A potential hydrogen bond between these
residues is shown. (D) Swapping arginine to histidine at the R1398-equivalent site prevent hydrogen bonding to S1671. (E) Comparison of the sequence around
R1398 and S1671 in human LRRK2 with those in human LRRK1 and C. tepidum Roco protein. Note that a serine at the 1671-position is conserved in mammalian
LRRK2 proteins and amongst Roco proteins in lower organisms. By contrast, LRRK1 proteins contain a histidine residue at this position.
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FIGURE 4 | R1398H decreases the fraction of LRRK2 in the GTP-bound ‘on’-state and increases GTPase activity. (A,B) GTP binding assays reveal
decreased binding of R1398H mutant LRRK2 to GTP-sepharose compared to wild-type. (A) Shows a representative experiment; (B) the mean of three independent
experiments (one-way ANOVA for effect of genotype, F = 48.475, p < 0.001) with p-values from post hoc Dunnett’s testing indicated. Values were adjusted to the
amount of transfected LRRK2 in cell lysates; gels were re-probed for calnexin to show protein loading and to confirm the purity of GTP-bound protein. (C) A protein
gel showing the purity and concentration of FLAG-tagged LRRK2 protein to be used in GTPase assays. The masses (kDa) of the molecular weight marker bands are
shown. (D) GTP hydrolysis assays reveal that the R1398H mutant displays greater GTPase activity than wild-type LRRK2. Two-way ANOVA with repeated measures
and a Greenhouse–Geisser correction revealed significant effects of time (F = 224.221; p < 0.001), genotype (F = 24.06; p < 0.001) and interaction between time
and genotype (F = 7.021; p < 0.001). p-values from post hoc two-sided Dunnett’s tests are shown. Value are the means of four independent experiments. Error
bars represent the standard error of the mean.
group of a conserved serine in the COR domain (S778 in
Roco, S1671 in LRRK2, predicted hydrogen bond distance:
2.776 Å). This is an intriguing possibility, since the R1441C/G
and Y1699C pathogenic mutations have also been predicted to
modify intramolecular RocCOR interactions (Gotthardt et al.,
2008; Daniëls et al., 2011). In agreement, conversion of R1398
to the much shorter histidine – representative of R1398H –
prevented bonding with the conserved serine (Figure 3D). Taken
together, our molecular modeling suggests that the observed
increase in intermolecular RocCOR dimerization caused by
R1398H (Figure 2) likely occurs via an indirect mechanism,
involving changes to intramolecular interactions between Roc
and COR domains.
R1398H Decreases the Fraction of
GTP-Bound LRRK2
Numerous reports indicate that PD-causing mutations in the
LRRK2 RocCOR tandem domain increase the ratio of GTP-
bound (‘on’) LRRK2 to GDP-bound (‘off ’) LRRK2, by weakening
GTPase activity and/or facilitating GTP binding (Table 1). In
principle, a protective amino acid substitution located within
this portion of LRRK2 would be expected to have the opposite
effect. Thus, the effect of the R1398H variant on LRRK2
GTPase function was examined directly, using full-length human
LRRK2 expressed in mammalian cells. Firstly, this variant was
studied in GTP binding assays. As reported by others, wild-
type LRRK2 bound strongly to immobilized GTP, whilst a
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FIGURE 5 | R1398H increases canonical Wnt signaling. (A) R1398H
increases the activation of the TOPflash reporter by DVL1 relative to wild-type
LRRK2, whilst the R1441G mutant and G2385R LRRK2 risk variant
decreases reporter activation (one-way ANOVA for effect of genotype,
F = 20.666, p < 0.001). (B) All LRRK2 mutant constructs express at an
equivalent level to wild-type LRRK2. Values shown are the means of at least
three independent experiments performed in triplicate, and are normalized to
control experiments performed in parallel using the FOPflash reporter plasmid.
p-values from post hoc two-way Dunnett’s testing are indicated (WT, n = 21;
R1398H, n = 9; R1441G, n = 12; G2385R, n = 12). Error bars represent the
standard error of the mean.
well-characterized mutant, LRRK2 T1348N, had negligible GTP-
binding capacity (Figures 4A,B). Strikingly, the R1398H variant
also displayed weakened GTP binding (∼47% of wild-type),
although this value was more than threefold greater than for
T1348N LRRK2, indicating that GTP binding is not abolished
entirely.
We next examined the effect of the LRRK2 R1398H variant
on GTP hydrolysis in vitro, using steady-state GTPase assays.
FLAG-tagged wild-type LRRK2, and LRRK2 containing T1348N
and R1398H amino acid substitutions were purified from
HEK293 cells (Figure 4C), and equimolar amounts were used
in subsequent experiments (Figure 4D). This protein produced
a steady turnover of GTP, confirming that wild-type LRRK2
possesses intrinsic GTPase activity (Figure 4D, open circles).
Unsurprisingly, since T1348N LRRK2 is almost unable to bind
GTP, this mutant possessed very little GTPase activity, with
GTP hydrolysis undetectable until the 20 min time point
(Figure 4D, gray circles). However, R1398H LRRK2 showed a
marked increase in GTP hydrolysis relative to wild-type LRRK2
(Figure 4D, black triangles). In summary, the protective R1398H
LRRK2 variant weakens GTP binding but increases steady-state
GTP hydrolysis, both of which are consistent with a decrease in
the proportion of GTP-bound LRRK2.
The Protective R1398H LRRK2 Variant
Increases Canonical Wnt Signaling
We have previously reported that PD-causing mutations in
the Roc, COR and kinase domains of LRRK2 weaken the
activation of canonical Wnt signaling that is elicited by disheveled
(DVL) proteins (Berwick and Harvey, 2012). Consistent with
this finding, the LRRK2 R1441G pathogenic mutant and
importantly the WD40 domain G2385R PD risk variant also
reduce pathway activation relative to wild-type LRRK2 in SH-
SY5Y cells (Figure 5A). By contrast, LRRK2 R1398H enhanced
DVL1-driven Wnt activation almost twice as much as wild-
type LRRK2 (Figure 5A). This opposing effect of the protective
LRRK2 variant to that described for pathogenic variants in four
distinct LRRK2 domains is notable, and cannot be attributed
to altered expression levels (Figure 5B). These experiments
suggest a strong correlation between PD risk conferred by LRRK2
variants and regulation of canonical Wnt signaling activity.
To further examine a possible causal mechanism that
affects canonical Wnt signaling, we investigated the interaction
between the LRRK2 R1398H variant and the canonical Wnt
co-receptor LRP6 in Q-YTH experiments. Using the LRP6
intracellular domain as bait and the LRRK2 RocCOR tandem
domain as prey, we observed a decrease in the interaction
strength with the R1398H protective variant relative to wild-
type LRRK2 (Supplementary Figures S1A,B). Since pathogenic
LRRK2 GTPase mutants also show a decrease in protein–
protein interaction (Supplementary Figure S1A, Berwick and
Harvey, 2012) altered LRRK2-LRP6 interactions do not explain
the increase in canonical Wnt signaling activity of the R1398H
protective variant relative to the decrease observed for pathogenic
LRRK2 variants.
Protective R1398H LRRK2 Variant
Increases Axon Length in Cultured
Cortical Neurones
Temporary differences in neurite outgrowth between LRRK2
knockout, mutant and wild-type neurones have been reported
in various experimental systems (MacLeod et al., 2006; Dächsel
et al., 2010; reviewed by Gómez-Suaga et al., 2014). As LRRK2
GTPase activity and Wnt signaling activity (Salinas, 2012;
Gómez-Suaga et al., 2014) affect neurite outgrowth, we decided
to examine axon length and branching as a correlate for neurite
outgrowth and complexity in rat cortical neurones in primary
culture overexpressing LRRK2 wild-type and variants at 7 DIV.
Over-expression of wild-type LRRK2 had no effect on mean
axonal length (p = 0.082) or axon branching (p = 0.695)
relative to neurones transfected with empty vector control
(Supplementary Figure S2). Furthermore, no difference in axon
branching was observed between the different LRRK2 genotypes
(Kruskal–Wallis χ2 = 0.943, p= 0.815; Figure 6B). However, the
overexpression of LRRK2 mutants had a marked effect on axon
length (F = 23.52, p < 0.001; Figure 6C). In agreement with
previous work, neurones overexpressing the pathogenic LRRK2
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FIGURE 6 | The protective R1398H LRRK2 variant increases axonal length in primary cortical neuronal cultures. Rat primary neurones were transfected
with wild-type LRRK2 or the indicated variants prior to fixation and staining for axonal tau protein after 7 DIV. (A) Shows representative images of LRRK2-transfected
neurones. (B) Quantification of the number of axon branches per neurone reveals no effect of R1441G or R1398H mutations (WT, n = 49; R1398H, n = 26;
R1441G, n = 38; R1398H/R1441G, n = 31). (C) By contrast, R1398H increases axonal length and rescues the decrease in length caused by the pathogenic
R1441G mutant (WT, n = 49; R1398H, n = 32; R1441G, n = 56; R1398H/R1441G, n = 39). (D) All LRRK2 mutant constructs were expressed at an equivalent level
to wild-type LRRK2. Scale bar: 30 µm. p-values from post hoc Bonferroni tests are shown. Error bars represent the standard error of the mean.
R1441G mutant showed a reduction in axon length relative to
wild-type LRRK2 (MacLeod et al., 2006; Cho et al., 2013). By
contrast, the protective R1398H variant increased axon length
in comparison to wild-type overexpressing cells. Remarkably,
R1398H was able to rescue the effect of R1441G, as a double
R1398H/R1441G mutant phenocopied the effect of the R1398H
single mutant (Figure 6).
DISCUSSION
Our data provide robust experimental evidence consistent with
the idea that the familial LRRK2 R1398H variant is protective
against PD. Firstly, in contrast to the pathogenic R1441C,
R1441G, R1441H, and Y1699C variants (Figure 2A; Klein
et al., 2009; Daniëls et al., 2011; Law et al., 2014), R1398H
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FIGURE 7 | R1398 is located in close proximity to the N1437, R1441,
and Y1699 PD mutants location. A magnified image of the C. tepidum
Roco protein structure showing the close spatial proximity of R1398 to three
sites of pathogenic mutation, N1437, R1441, and Y1699. Mutations at all four
residues are expected to alter intramolecular interactions between Roc and
COR domains. Note that A1442 has also been implicated as the site of a
PD-causing mutation (Huang et al., 2007).
increases LRRK2 RocCOR domain dimerization (Figure 2).
Secondly, our molecular modeling suggests that this amino
acid substitution will affect the interaction between the Roc
and COR domains of the same molecule (Figure 3). Similarly,
the R1441C/G/H and Y1699C mutations, and indirectly the
N1437H mutation, have been suggested to affect intramolecular
RocCOR interactions and consequently RocCOR dimerization
as a proposed molecular pathomechanism (Gotthardt et al.,
2008; Klein et al., 2009; Daniëls et al., 2011). Thirdly, our
GTP-binding and GTP hydrolysis assays point toward R1398H
decreasing the ratio of GTP-bound to GDP-bound LRRK2. This
is in direct contrast to PD-causing mutations in the LRRK2
RocCOR tandem domain (Table 1). Fourthly, the R1398H
protective variant increases axon length in cortical neurones,
whereas LRRK2 mutants cause shortening of axons in equivalent
assays (Figure 6, MacLeod et al., 2006; Dächsel et al., 2010;
reviewed by Gómez-Suaga et al., 2014). And fifthly, R1398H
has the opposite effect to pathogenic mutations and variants
located throughout LRRK2 in cellular assays of canonical Wnt
activity (Figure 5; Berwick and Harvey, 2012). Taken together,
we believe our data make a persuasive case in support of the
genetic evidence that the R1398H variant is a genuine protective
variant.
Curiously, structure-based alterations at the R1398 site have
already been studied in assays of LRRK2 GTPase function and
produced results that are consistent with our R1398H data. This
is encouraging, since mutation of R1398 to any other amino
acid can be expected to prevent hydrogen bonding to S1671.
The best-studied structure-based LRRK2 R1398 mutant, R1398L,
was designed from Ras GTPase homology models, with the
expectation that it would behave similarly to the Q61L amino acid
substitution that renders Ras proteins ‘GTP-locked.’ However,
R1398L had the opposite effect. This change increased GTPase
activity, both in full-length LRRK2 and in a deletion construct
containing the Roc, COR and kinase domains of LRRK2
(RocCOR-kinase; Xiong et al., 2010; Stafa et al., 2012; Biosa et al.,
2013). R1398L also weakened GTP-binding in RocCOR-kinase
constructs, although no effect was seen in full-length LRRK2
(Xiong et al., 2010; Biosa et al., 2013). Although in disagreement
with expectations, these data are clearly in accordance with
our results for LRRK2 R1398H. An R1398Q mutant was also
studied, with the rationale that this mutation would render
LRRK2 more like wild-type Ras, but no statistically significant
changes to GTP-binding or GTP hydrolysis were detected using
full-length LRRK2 (Biosa et al., 2013). However, when R1398Q
was introduced into a RocCOR-kinase construct alongside a
second Ras-like amino acid substitution, T1343G, GTP-binding
was decreased and GTP hydrolysis increased (Xiong et al., 2010).
As mentioned, PD-causing mutations outside the RocCOR
tandem domain do not appear to operate via the same
mechanism as those affecting GTPase function, i.e., they do not
shift LRRK2 GTPase toward the GTP-bound ‘on’-state. This is
curious, since logic would dictate that the effects of all PD-causing
mutations in LRRK2 should converge on the same process or
processes eventually. By extension, a protective variant would be
expected to affect the same process, but in the opposite direction.
With this in mind, it is striking that the protective LRRK2
R1398H variant appears to enhance canonical Wnt signaling.
This observation is opposite to our data for pathogenic mutations
throughout the catalytic core of LRRK2 (Berwick and Harvey,
2012), and a PD risk variant in the C-terminal WD40 domain
(Figure 7).
Our data add to the growing body of evidence indicating that
deregulation of canonical Wnt signaling is involved in LRRK2
PD (Berwick and Harvey, 2014). Previous studies have revealed
that LRRK2 interacts with DVL proteins that play a central role
in all branches of Wnt signaling: (i) canonical; (ii) planar cell
polarity (PCP); and (iii) Wnt/Ca2+-signaling (Sancho et al., 2009;
Berwick and Harvey, 2012). LRRK2 also interacts with multiple
components of the β-catenin destruction complex in vivo
and associates with the Wnt co-receptor LRP6 at membranes.
Importantly, expression of familial LRRK2 mutants results in
decreased activation of Wnt/β-catenin signaling (Berwick and
Harvey, 2012). Strikingly, in this study we show that the R1398H
mutant has the opposite effect.
Our data also have implications beyond LRRK2 PD. Wnt
signaling pathways have emerged as essential regulators of
neuronal development and maintenance (Inestrosa and Arenas,
2010). Wnt ligands are known to activate signaling pathways
that lead to remodeling of the cytoskeleton and promote neurite
outgrowth via small GTPases (Inestrosa and Arenas, 2010).
Deficiencies in Wnt signaling pathways have been shown to
affect synaptic stability in the striatum (Arenas, 2014), whilst
antagonism of canonical Wnt signaling in the substantia nigra
promotes dopaminergic neurone death (L’Episcopo et al., 2014).
Wnt signaling is also important in the interplay between
the immune system (astrocytes, microglia) and neurones, and
deregulation affects adult neurogenesis (SVZ plasticity) with age
(L’Episcopo et al., 2014). Furthermore, both aging and neurotoxin
exposure are reported to down-regulate canonical Wnt signaling
in the adult midbrain, thereby increasing the vulnerability
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of dopaminergic neurones. Taken together these observation
provide strong evidence that Wnt signaling regulates multiple cell
biological functions in the midbrain dopaminergic neurones that
degenerate in PD, and that the age-related decrease in canonical
Wnt activity may have a central role in the pathogenesis of
sporadic forms of PD.
CONCLUSION
Our data support a model where pathogenic RocCOR mutants
display altered intramolecular RocCOR interactions, leading to
weakened RocCOR dimerization, increased GTP binding and
decreased GTP hydrolysis. Together, these effects lead to a greater
proportion of LRRK2 molecules existing in the GTP-bound
‘on’-state. The protective R1398H Roc domain mutation also
affects RocCOR interactions but with the opposite result, leading
to more LRRK2 in the ‘off ’-state. As such, developing small
molecules to decrease LRRK2 GTP-binding and/or stimulate
LRRK2 GTPase activity seems a promising strategy for the
development of PD modifying treatments and has already shown
some encouraging results in LRRK2 GTP and kinase domain
mutant PD models (Li et al., 2014, 2015).
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